Natalie Callendar
1 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| Phase II Study of Immunomaintenance Using POmalidomide With Elotuzumab afteR Second Autologous Transplant (NCT04584307) | Natalie Callendar | 2021-04-01 |
Track Natalie Callendar automatically
Every clearance here is in the API, with alerts when new ones post.